Asset Details
Do you wish to reserve the book?
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Do you wish to request the book?
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
2023
Overview
mRNA-based vaccines dramatically reduce the occurrence and severity of COVID-19, but are associated with rare vaccine-related adverse effects. These toxicities, coupled with observations that SARS-CoV-2 infection is associated with autoantibody development, raise questions whether COVID-19 vaccines may also promote the development of autoantibodies, particularly in autoimmune patients. Here we used Rapid Extracellular Antigen Profiling to characterize self- and viral-directed humoral responses after SARS-CoV-2 mRNA vaccination in 145 healthy individuals, 38 patients with autoimmune diseases, and 8 patients with mRNA vaccine-associated myocarditis. We confirm that most individuals generated robust virus-specific antibody responses post vaccination, but that the quality of this response is impaired in autoimmune patients on certain modes of immunosuppression. Autoantibody dynamics are remarkably stable in all vaccinated patients compared to COVID-19 patients that exhibit an increased prevalence of new autoantibody reactivities. Patients with vaccine-associated myocarditis do not have increased autoantibody reactivities relative to controls. In summary, our findings indicate that mRNA vaccines decouple SARS-CoV-2 immunity from autoantibody responses observed during acute COVID-19.
Whilst SARS-CoV-2 mRNA vaccines have demonstrated efficacy in reducing infection severity, research has shown that SARS-CoV-2 infection is associated with new autoantibodies. Whether this would also be observed during mRNA vaccination is unclear. Here, the authors use an autoantibody screening platform to monitor autoantibody responses in a diverse cohort during vaccination.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 49/47
/ Antibodies, Viral - immunology
/ Antigens
/ Autoimmune Diseases - immunology
/ COVID-19
/ COVID-19 - prevention & control
/ COVID-19 Vaccines - adverse effects
/ COVID-19 Vaccines - immunology
/ COVID-19 Vaccines - therapeutic use
/ Drug-Related Side Effects and Adverse Reactions - immunology
/ Humanities and Social Sciences
/ Humans
/ Immunity
/ Immunity, Humoral - immunology
/ mRNA
/ mRNA Vaccines - adverse effects
/ mRNA Vaccines - therapeutic use
/ Science
/ Severe acute respiratory syndrome coronavirus 2
/ Vaccines
/ Vaccines, Synthetic - adverse effects
/ Vaccines, Synthetic - immunology
